This excerpt taken from the AMLN DEFA14A filed May 11, 2009.
THE EXENATIDE ONCE WEEKLY OPPORTUNITY
Within the next two decades, cases of diabetes are estimated to grow by 55% globally. Last year there were over 23 million people with diabetes in the United States alone. Exenatide once weekly will be the first once-a-week treatment for type 2 diabetes and has the potential to transform the treatment of the disease. Industry experts have recognized the significance and commercial potential of exenatide once weekly:
· Many analysts believe that if [exenatide once weekly] makes it through [the FDA approval process it] may be a blockbuster, maybe even a mega blockbuster drug.
- Mike Huckman, CNBC, Pharmaceutical Reporter, May 5, 2009
· We believe exenatide [once weekly], once approved as the first once-weekly agent from the GLP-1 class, should help drive the company toward sustainable profitability.
- Matthew Osborne, Senior Biotechnology Analyst, Lazard, April 30, 2009